Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
- 25 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (5) , 562-568
Abstract
The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.Keywords
This publication has 25 references indexed in Scilit:
- Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyCancer Science, 2019
- Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencingBMC Medical Informatics and Decision Making, 2019
- Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real lifeCritical Reviews in Oncology/Hematology, 2019
- Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologyJAMA Oncology, 2018
- The clinical impact of using complex molecular profiling strategies in routine oncology practiceOncotarget, 2018
- Precision oncology: separating the wheat from the chaffESMO Open, 2018
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerThe Journal of Molecular Diagnostics, 2017
- Challenges of Identifying Clinically Actionable Genetic Variants for Precision MedicineJournal of Healthcare Engineering, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982